The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function

计划入组 19 人 · 首次发布于 2007 年 9 月 10 日

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

计划入组 12 人 · 首次发布于 2005 年 9 月 13 日

Hyperalgesia and NMDA Receptor Antagonist

计划入组 90 人 · 首次发布于 2014 年 3 月 14 日

NMDA receptor antagonists (NR2B subtype-selective) (Merck & Co)

NMDA receptor antagonists (Shionogi)

NMDA receptor antagonists(Pfizer)

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

Veru Inc

United States

GNT Pharma's Nelonemdaz Shows Promise in Improving Stroke Outcomes with Early Administration

FDA Grants Breakthrough Therapy Status to Radiprodil for GRIN-Related Seizure Treatment

Novel NMDA Receptor Modulator Onfasprodil Shows Rapid Antidepressant Effects with Reduced Side Effects in Phase 2 Trial